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Abstract Wound healing after dermal injury is an im-
perfect process, inevitably leading to scar formation as the
skin re-establishes its integrity. The resulting scars have
different characteristics to normal skin, ranging from fine-
line asymptomatic scars to problematic scarring including
hypertrophic and keloid scars. Scars appear as a different
colour to the surrounding skin and can be flat, stretched,
depressed or raised, manifesting a range of symptoms
including inflammation, erythema, dryness and pruritus,
which can result in significant psychosocial impact on
patients and their quality of life. In this paper, a com-
prehensive literature review coupled with an analysis of
levels of evidence (LOE) for each published treatment
type was conducted. Topical treatments identified include
imiquimod, mitomycin C and plant extracts such as onion
extract, green tea, Aloe vera, vitamin E and D, applied to
healing wounds, mature scar tissue or fibrotic scars fol-
lowing revision surgery, or in combination with other
more established treatments such as steroid injections and
silicone. In total, 39 articles were included, involving
1703 patients. There was limited clinical evidence to
support their efficacy; the majority of articles (n = 23)
were ranked as category 4 LOE, being of limited quality
with individual flaws, including low patient numbers,
poor randomisation, blinding, and short follow-up periods.
As trials were performed in different settings, they were
difficult to compare. In conclusion, there is an unmet
clinical need for effective solutions to skin scarring, more
robust long-term randomised trials and a consensus on a
standardised treatment regime to address all aspects of
scarring.
Keywords Skin scarring  Wound repair  Keloid
disease  Hypertrophic scarring  Topical therapy
Abbreviations
ECM Extracellular matrix
PDT Photodynamic therapy
ES Electrical stimulation
POSAS Patient and Observer Scar Assessment Scale
TAC Triamcinolone
5-FU 5-Fluorouracil
EGCG (-)-Epigallocatechin-3-gallate
MEBO Moist exposure burn ointment
LOE Levels of evidence
SIAscopy Spectrophotometric intracutaneous analysis
Introduction
The process of wound healing after injury to the skin is
complex, with many overlapping mechanisms involved
including inflammation, proliferation and tissue remod-
elling [54]. The inflammation phase takes place in the
first 48 h following injury triggering a signalling cascade
[50, 77], with neutrophils and macrophages accumulating
at the wound site to prevent infection [50, 112]. Fi-
broblasts begin to synthesise a wide range of
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extracellular matrix molecules (ECM) during the prolif-
erative phase, repairing the wound and restoring the
structure and function of the skin, with new blood ves-
sels formed to restore circulation [35, 104]. The process
of remodelling leads to a more formal and cross-linked
arrangement of the ECM as the scar matures [100]
which can last up to a year [21].
Scarring is an imperfect mechanism; an evolutionary
compromise made to restore tissue integrity, preventing
infection at the expense of appearance. Scars take many
forms, depending on size and severity, the type of injury
and the anatomical location [7]. Many heal to become fine-
line asymptomatic scars, but some lead to abnormal scar-
ring (Fig. 1). There is a spectrum of pathological skin scars
ranging from stretched, depressed and/or contracted, to
raised dermal scars such as hypertrophic and keloid scars,
categorised by over-expression of ECM during the prolif-
erative and remodelling phases of wound healing, which
may have a genetic element in certain individuals [16, 19,
99–101]. While sharing characteristics of being raised,
keloid scars progress beyond the boundaries of the original
wound and do not regress over time unlike hypertrophic
scars [21, 70]. Thus, clinical misdiagnosis between the two
can complicate findings of clinical trials in management of
raised dermal scarring.
Scar scales are used to assess severity from a clinical
and patient perspective [45, 95]. These include the Van-
couver Scar Scale [108], the Manchester Scar Scale [8],
and specialised scales for burns [118] and keloids [83]. All
assess symptoms including inflammation, redness (erythe-
ma) or colour compared with the surrounding skin, size,
scar contour, dryness and itchiness (pruritus). However, no
scar scale is perfect; each scale evaluates a different set of
criteria using a variable number of criteria, and often re-
lying on the subjective interpretation of individual clin-
ician, making it difficult to compare assessments between
studies. The patient-reported impact of scars measure
(PRISM) [18] is useful as patients perceive scarring dif-
ferently to clinicians [41, 46]. This psychological dimen-
sion is relevant as skin scarring, which is visible or cannot
be hidden by clothing or makeup, can impact on self-es-
teem and quality of life [15, 17, 111, 114].
Different treatment options are available to aid the
scarring process, in particular focusing on severe types of
scarring. Some, such as electrical stimulation [20, 49, 84,
90], photodynamic therapy [68, 85] and steroids are only
available in a clinical setting. The most cited treatment
option for keloids is surgical excision, followed by com-
bination therapy including intralesional steroid injections,
most commonly triamcinolone (TAC), with silicone gel or
sheeting and/or pressure bandages [13, 102]. However,
recurrence rates following keloid revision surgery are high
and are difficult to define, varying considerably
(40–100 %) depending on the application and adherence to
the recommended and prescribed treatment options, the
location of the original scar (with keloids excised from the
earlobes recurring less frequently than those from the
sternum or back) and the follow-up period of the study [2,
16]. Hydration and occlusion, facilitated by silicone gels
and sheeting, are thought to potentially influence burn,
hypertrophic and keloid scar maturation [1, 26, 92, 97,
117], suppressing the inflammatory response triggered by
keratinocytes and the epidermis in response to a compro-
mised stratum corneum [81]. The administration of TAC as
a control in combination with other treatments is a common
approach to assess efficacy of new treatments; for example,
with 5-fluorouracil (5-FU) [3, 38, 52, 115] and verapamil, a
calcium channel blocker which stimulates procollagenase
synthesis [37, 74].
A number of prescription and over-the-counter topical
remedies are available, which claim to alleviate symptoms
Fig. 1 A representation of different types of skin scarring and scar
types, as often observed, for example following a mid-sternal
incision, post-cardiac surgery. a Fine-line scar, b hypertrophic scar,
c intermediate raised dermal scar, d keloid scar
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and improve the appearance of scars and accelerate the
rate of wound healing. Topical therapies have their ad-
vantages; specifically, increased adherence, the localised
delivery of product and the reduced effect of first pass
metabolism [107]. Patients often self-medicate indepen-
dently of clinician care following injury or surgery to treat
specific signs and symptoms of concern. Patients only
report these concerns and seek diagnosis and treatment,
should signs and symptoms worsen, most commonly, in
the case of hypertrophic and keloid scarring, leading to a
more radical approach being required. There is no com-
prehensive review of the efficacy of many of these readily
available treatments and the quality of research published
utilising over-the counter or topical treatments, nor is
there a standardised diagnosis and treatment protocol for
problematic skin scarring aimed at treating specific signs
and symptoms. The aim of this review is to summarise
these treatment options and interpret their effectiveness
from the published clinical data, in comparison to other
approaches, while proposing a more formal approach for
treating symptoms of healing wounds, scars and fibrotic
scarring such as keloid scarring.
Methods
A literature search was conducted in Pubmed and Scopus
to identify relevant English language literature published in
the field of topical treatments for wound healing and keloid
and hypertrophic scarring, as alternatives to the commonly
utilised silicone and intralesional steroid therapies. Terms
included combinations of ‘‘wound’’, ‘‘healing’’, ‘‘skin’’,
‘‘scar’’, ‘‘burn’’, ‘‘keloid’’ and ‘‘topical’’, and were further
refined to include the names of individual therapies iden-
tified during the search. Key review papers in the field were
also consulted. Identified articles were archived in Endnote
XI (Thompson Reuters, USA), and duplicates removed.
The titles and abstracts of all identified literature were
assessed to determine their relevance to the objectives of
the review. The reference lists of identified articles were
then searched in order to identify further publications of
interest. The search focused on clinical trials published
since 2000 relating to the effect of skin topicals on healing
wounds following surgery, new or mature scars and fibrotic
scarring, with an outcome measure of improving the re-
sulting scar quality or reducing the rate of keloid recur-
rence following revision surgery. Studies in animal or cell
culture models were not considered beyond adding context
in relation to methods of action. Once identified as being
appropriate for inclusion, individual trials were then
assessed using the Oxford Level of Evidence (LOE) pro-
tocol, to establish the validity and robustness of the data
presented (Table 1) [60–62].
Results
A considerable range of trials were evaluated for inclusion
in this review, from systematic reviews and randomised
controlled trials to case/control studies and pilot studies,
focussing on different topical treatment options for wound
healing, normal scarring and burns as well as for keloid and
hypertrophic scars. In some instances individual therapies
were trialled on their own, or in combination with more
established therapeutic approaches, such as steroid injec-
tions, or following revision surgery. These studies were
assessed on a case-by-case basis, and were included if the
outcome measure demonstrated the benefit or otherwise of
the topical therapy intervention compared with standard-
ised treatment—with respect to the quality and properties
of the resulting scar as determined by the appropriate scar
scales, and in the case of keloid scarring with respect to
recurrence following surgery. All trials identified for in-
clusion are summarised in detail in Table 2. For each
treatment option, listed below, an overview is given fol-
lowed by its effect on the symptoms of normal scarring,
burns and fibrotic scarring.
Imiquimod
Imiquimod is an immune response modifier, typically
formulated as a 5 % cream, used in a range of dermato-
logical conditions such as warts and other viral-associated
conditions [9]. Ten different articles were identified for
inclusion, treating 193 patients [10–12, 23, 33, 73, 76, 89,
93, 105]. Of these studies, just one was a randomised
double-blind controlled trial [10] ranked as LOE 2, the rest
were case studies and case controlled studies ranked as
Table 1 Ranking of studies and clinical trials by their respective
levels of evidence (LOE), as defined by the Oxford Centre for Evi-
dence Based Medicine [60–62]
Level of
evidence
Study type
1 Systematic review of RCT
High-quality RCT
2 Systematic review of cohort studies
Low-quality RCT
Cohort studies/non-randomised controlled trial
3 Systematic review of case–control studies
Case–control studies
4 Case series
Low-quality case–control studies
Low-quality cohort studies/non-randomised
controlled trial
5 Case reports
Expert opinions
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4
G
u
p
ta
an
d
N
ar
an
g
[5
3
]
n
=
2
0
,
In
d
ia
C
as
e
st
u
d
y
an
d
li
te
ra
tu
re
re
v
ie
w
T
o
p
ic
al
m
it
o
m
y
ci
n
C
fo
ll
o
w
in
g
ea
rl
o
b
e
k
el
o
id
sh
av
e
ex
ci
si
o
n
.
P
at
ie
n
t
an
d
cl
in
ic
ia
n
s
ra
te
d
sy
m
p
to
m
s
o
n
li
n
ea
r
an
al
o
g
u
e
sc
al
e
(s
ca
r
sc
al
e
u
ti
li
se
d
n
o
t
d
efi
n
ed
).
6
–
2
4
m
o
n
th
s
fo
ll
o
w
-
u
p
P
o
si
ti
v
e—
n
o
k
el
o
id
re
cu
rr
en
ce
d
u
ri
n
g
fo
ll
o
w
-u
p
p
er
io
d
4
S
eo
an
d
S
u
n
g
[9
8
]
n
=
9
,
K
o
re
a
C
as
e
st
u
d
y
T
o
p
ic
al
m
it
o
m
y
ci
n
C
fo
ll
o
w
in
g
k
el
o
id
ex
ci
si
o
n
.
R
ec
u
rr
en
ce
an
d
sy
m
p
to
m
s
as
se
ss
ed
v
ia
V
an
co
u
v
er
S
ca
r
S
ca
le
an
d
p
at
ie
n
t
sa
ti
sf
ac
ti
o
n
al
so
ra
te
d
.
6
m
o
n
th
s
fo
ll
o
w
-u
p
P
o
si
ti
v
e—
si
x
o
u
t
o
f
n
in
e
w
er
e
sa
ti
sfi
ed
,
n
o
n
e
w
er
e
d
is
ap
p
o
in
te
d
.
In
tr
al
es
io
n
al
tr
ea
tm
en
t
ag
g
ra
v
at
ed
th
e
sc
ar
4
S
an
d
er
s
et
al
.
[9
6
]
n
=
1
5
,
U
S
A
C
as
e
st
u
d
y
—
p
at
ie
n
ts
h
ad
m
u
lt
ip
le
k
el
o
id
s
an
d
ac
te
d
as
th
ei
r
o
w
n
u
n
tr
ea
te
d
co
n
tr
o
l
T
o
p
ic
al
m
it
o
m
y
ci
n
C
fo
ll
o
w
in
g
k
el
o
id
ex
ci
si
o
n
,
fo
ll
o
w
ed
b
y
in
tr
al
es
io
n
al
T
A
C
af
te
r
1
m
o
n
th
.
R
ec
u
rr
en
ce
an
d
sy
m
p
to
m
s
as
se
ss
ed
b
y
cl
in
ic
ia
n
(s
ca
r
sc
al
e
u
ti
li
se
d
n
o
t
d
efi
n
ed
).
4
–
2
8
m
o
n
th
s
fo
ll
o
w
-u
p
N
eg
at
iv
e/
n
eu
tr
al
—
n
o
d
if
fe
re
n
ce
in
re
sp
o
n
se
w
it
h
o
r
w
it
h
o
u
t
m
it
o
m
y
ci
n
C
4
T
al
m
i
et
al
.
[1
1
0
]
n
=
8
,
Is
ra
el
C
as
e
st
u
d
y
T
o
p
ic
al
m
it
o
m
y
ci
n
C
fo
ll
o
w
in
g
k
el
o
id
ex
ci
si
o
n
.
R
ec
u
rr
en
ce
an
d
sy
m
p
to
m
s
as
se
ss
ed
b
y
cl
in
ic
ia
n
(s
ca
r
sc
al
e
u
ti
li
se
d
n
o
t
d
efi
n
ed
)
an
d
p
at
ie
n
t
sa
ti
sf
ac
ti
o
n
al
so
ra
te
d
.
2
m
o
n
th
s
fo
ll
o
w
-u
p
N
eg
at
iv
e/
n
eu
tr
al
—
p
at
ie
n
ts
sa
ti
sfi
ed
w
it
h
o
u
tc
o
m
e,
h
o
w
ev
er
,
to
ta
l
d
is
ap
p
ea
ra
n
ce
w
as
o
n
ly
se
en
in
2
p
at
ie
n
ts
4
D
ra
el
o
s
et
al
.
[4
3
]
n
=
4
4
,
U
S
A
R
an
d
o
m
is
ed
co
n
tr
o
ll
ed
si
n
g
le
-b
li
n
d
ed
tr
ia
l—
p
at
ie
n
t
ac
te
d
as
o
w
n
u
n
tr
ea
te
d
co
n
tr
o
l
T
o
pi
ca
la
pp
li
ca
ti
on
o
f
p
ro
pr
ie
ta
ry
on
io
n
ex
tr
ac
tc
re
am
(M
ed
er
m
a
)
(4
w
ee
k
s,
o
n
ce
d
ai
ly
)
fo
ll
o
w
in
g
su
rg
er
y
fo
r
se
b
o
rr
h
ei
c
k
er
at
o
se
s.
S
y
m
p
to
m
s
as
se
ss
ed
b
y
cl
in
ic
ia
n
u
si
n
g
4
-p
o
in
t
sc
al
e
(s
ca
r
sc
al
e
u
ti
li
se
d
n
o
t
d
efi
n
ed
).
F
o
ll
o
w
-u
p
1
0
w
ee
k
s
P
o
si
ti
v
e—
si
g
n
ifi
ca
n
t
im
p
ro
v
em
en
t
in
ap
p
ea
ra
n
ce
co
m
p
ar
ed
w
it
h
tr
ea
te
d
co
n
tr
o
ls
1
Je
n
w
it
h
ee
su
k
et
al
.
[6
3
]
n
=
6
0
,
T
h
ai
la
n
d
R
an
d
o
m
is
ed
,
d
o
u
b
le
-
b
li
n
d
ed
p
la
ce
b
o
co
n
tr
o
ll
ed
tr
ia
l
T
o
p
ic
al
ap
p
li
ca
ti
o
n
o
f
si
li
co
n
e
±
o
n
io
n
ex
tr
ac
t
(C
y
b
el
e
sc
ag
el
)
fo
ll
o
w
in
g
su
rg
er
y
,
tw
ic
e
d
ai
ly
fo
r
1
2
w
ee
k
s.
S
y
m
p
to
m
s
as
se
ss
ed
v
ia
V
an
co
u
v
er
S
ca
r
S
ca
le
an
d
p
at
ie
n
t
sa
ti
sf
ac
ti
o
n
al
so
ra
te
d
.
1
2
w
ee
k
s
fo
ll
o
w
-u
p
P
o
si
ti
v
e—
u
si
n
g
V
an
co
u
v
er
S
ca
r
S
ca
le
,
p
ai
n
it
ch
an
d
p
ig
m
en
ta
ti
o
n
w
er
e
im
p
ro
v
ed
in
o
n
io
n
ex
tr
ac
t-
tr
ea
te
d
g
ro
u
p
co
m
p
ar
ed
w
it
h
co
n
tr
o
l
1
H
o
et
al
.
[5
6
]
n
=
1
2
0
,
H
o
n
g
K
o
n
g
R
an
d
o
m
is
ed
co
n
tr
o
ll
ed
tr
ia
l
T
o
p
ic
al
ap
p
li
ca
ti
o
n
o
f
o
n
io
n
ex
tr
ac
t
(C
o
n
tr
at
u
b
ex

)
fo
ll
o
w
in
g
la
se
r
ta
tt
o
o
re
m
o
v
al
(t
w
ic
e
d
ai
ly
,
v
s
n
o
tr
ea
tm
en
t)
.
S
y
m
p
to
m
s
an
d
ap
p
ea
ra
n
ce
as
se
ss
ed
b
y
cl
in
ic
ia
n
(s
ca
r
sc
al
e
u
ti
li
se
d
n
o
t
d
efi
n
ed
).
3
m
o
n
th
s
fo
ll
o
w
-u
p
P
o
si
ti
v
e—
si
g
n
ifi
ca
n
tl
y
re
d
u
ce
d
th
e
ri
sk
o
f
sc
ar
ri
n
g
fr
o
m
2
3
.5
to
1
1
.5
%
2
H
o
su
n
te
r
et
al
.
[5
9
]
n
=
6
0
,
T
u
rk
ey
R
an
d
o
m
is
ed
tr
ia
l,
th
re
e
g
ro
u
p
s—
o
n
io
n
ex
tr
ac
t,
si
li
co
n
e
o
r
b
o
th
tr
ea
tm
en
ts
.
O
n
io
n
ex
tr
ac
t
(C
o
n
tr
at
u
b
ex

)
o
n
ex
is
ti
n
g
h
y
p
er
tr
o
p
h
ic
an
d
k
el
o
id
sc
ar
s,
fo
u
r
ti
m
es
p
er
d
ay
.
S
y
m
p
to
m
s
an
d
ap
p
ea
ra
n
ce
as
se
ss
ed
b
y
cl
in
ic
ia
n
(s
ca
r
sc
al
e
u
ti
li
se
d
n
o
t
d
efi
n
ed
).
F
o
ll
o
w
-u
p
6
m
o
n
th
s
N
eg
at
iv
e/
n
eu
tr
al
—
in
ef
fe
ct
iv
e
at
im
p
ro
v
in
g
sc
ar
h
ei
g
h
t
an
d
it
ch
.
B
es
t
re
sp
o
n
se
w
as
in
co
m
b
in
at
io
n
w
it
h
si
li
co
n
e
g
el
2
D
ra
el
o
s
[4
2
]
n
=
6
0
,
U
S
A
R
an
d
o
m
is
ed
tr
ia
l
T
o
p
ic
al
ap
p
li
ca
ti
o
n
o
f
o
n
io
n
ex
tr
ac
t
cr
ea
m
(M
ed
er
m
a
)
fo
ll
o
w
in
g
su
rg
er
y
fo
r
se
b
o
rr
h
ei
c
k
er
at
o
se
s.
S
y
m
p
to
m
s
an
d
ap
p
ea
ra
n
ce
as
se
ss
ed
b
y
cl
in
ic
ia
n
an
d
p
at
ie
n
t
(s
ca
r
sc
al
e
u
ti
li
se
d
n
o
t
d
efi
n
ed
).
F
o
ll
o
w
-u
p
1
0
w
ee
k
s
P
o
si
ti
v
e—
im
p
ro
v
em
en
t
in
sc
ar
ap
p
ea
ra
n
ce
co
m
p
ar
ed
w
it
h
u
n
tr
ea
te
d
co
n
tr
o
ls
3
C
h
u
an
g
su
w
an
ic
h
et
al
.
[3
2
]
n
=
1
5
,
T
h
ai
la
n
d
R
an
d
o
m
is
ed
b
li
n
d
ed
sp
li
t-
sc
ar
st
u
d
y
T
o
p
ic
al
ap
p
li
ca
ti
o
n
o
f
o
n
io
n
ex
tr
ac
t
(C
y
b
el
e
sc
ag
el
)
fo
ll
o
w
in
g
sk
in
g
ra
ft
.
S
y
m
p
to
m
s
as
se
ss
ed
v
ia
V
an
co
u
v
er
S
ca
r
S
ca
le
an
d
p
at
ie
n
t
sa
ti
sf
ac
ti
o
n
al
so
ra
te
d
.
1
2
w
ee
k
s
fo
ll
o
w
-u
p
P
o
si
ti
v
e—
im
p
ro
v
em
en
t
in
sc
ar
sc
al
e
re
su
lt
s
co
m
p
ar
ed
w
it
h
u
n
tr
ea
te
d
co
n
tr
o
l
3
Arch Dermatol Res (2015) 307:461–477 465
123
T
a
b
le
2
co
n
ti
n
u
ed
R
ef
er
en
ce
s
S
am
p
le
si
ze
/
C
o
u
n
tr
y
o
f
O
ri
g
in
S
tu
d
y
ty
p
e
T
re
at
m
en
t,
as
se
ss
m
en
t
an
d
fo
ll
o
w
-u
p
O
u
tc
o
m
e—
p
o
si
ti
v
e
o
r
n
eg
at
iv
e
fi
n
d
in
g
s?
L
ev
el
o
f
ev
id
en
ce
P
er
ez
et
al
.
[9
1
]
n
=
3
0
,
U
S
A
R
an
d
o
m
is
ed
,
b
li
n
d
ed
co
m
p
ar
at
iv
e
st
u
d
y
0
.5
%
h
y
d
ro
co
rt
is
o
n
e,
si
li
co
n
e
an
d
v
it
am
in
E
lo
ti
o
n
v
s
o
n
io
n
ex
tr
ac
t
g
el
.
K
el
o
id
an
d
h
y
p
er
tr
o
p
h
ic
sc
ar
s.
V
is
u
al
an
al
o
g
u
e
sc
al
e
u
se
d
to
as
se
ss
ap
p
ea
ra
n
ce
o
f
p
o
st
-s
u
rg
ic
al
w
o
u
n
d
s
b
y
cl
in
ic
ia
n
s
an
d
p
at
ie
n
ts
.
4
m
o
n
th
s
fo
ll
o
w
-u
p
P
o
si
ti
v
e—
b
o
th
tr
ea
tm
en
ts
m
o
re
ef
fe
ct
iv
e
th
an
p
la
ce
b
o
3
C
h
an
p
ra
p
ap
h
et
al
.
[2
7
]
n
=
2
0
,
T
h
ai
la
n
d
R
an
d
o
m
is
ed
sp
li
t
sc
ar
st
u
d
y
O
n
io
n
ex
tr
ac
t
g
el
(E
ra
se´
g
el
)
o
n
ca
es
ar
ea
n
sc
ar
s.
V
is
u
al
an
al
o
g
u
e
sc
al
e
u
se
d
to
as
se
ss
ap
p
ea
ra
n
ce
o
f
p
o
st
-s
u
rg
ic
al
w
o
u
n
d
s
b
y
cl
in
ic
ia
n
s
an
d
p
at
ie
n
ts
.
1
2
w
ee
k
s
fo
ll
o
w
-u
p
P
o
si
ti
v
e—
re
d
u
ct
io
n
in
m
ea
n
sc
ar
h
ei
g
h
t
an
d
sy
m
p
to
m
s
co
m
p
ar
ed
w
it
h
u
n
tr
ea
te
d
si
d
e
4
K
o
c
et
al
.
[6
9
]
n
=
2
7
,
T
u
rk
ey
O
p
en
,
ra
n
d
o
m
is
ed
co
m
p
ar
at
iv
e
st
u
d
y
O
n
io
n
ex
tr
ac
t
(C
o
n
tr
at
u
b
ex

)
(t
h
re
e
ti
m
es
d
ai
ly
fo
r
3
m
o
n
th
s)
v
s
in
tr
al
es
io
n
al
T
A
C
o
n
k
el
o
id
an
d
h
y
p
er
tr
o
p
h
ic
sc
ar
s
fo
r
3
m
o
n
th
s.
S
y
m
p
to
m
s
an
d
ap
p
ea
ra
n
ce
as
se
ss
ed
b
y
cl
in
ic
ia
n
an
d
p
at
ie
n
t
(s
ca
r
sc
al
e
u
ti
li
se
d
n
o
t
d
efi
n
ed
).
2
m
o
n
th
s
fo
ll
o
w
-u
p
P
o
si
ti
v
e—
b
o
th
in
tr
al
es
io
n
al
T
A
C
an
d
C
o
n
tr
ac
tu
b
ex
w
er
e
ef
fe
ct
iv
e,
co
m
b
in
at
io
n
th
er
ap
y
w
as
b
es
t
4
K
ar
ag
o
z
et
al
.
[6
5
]
n
=
4
5
,
T
u
rk
ey
R
an
d
o
m
is
ed
ca
se
–
co
n
tr
o
l
st
u
d
y
C
o
m
p
ar
is
o
n
o
f
si
li
co
n
e
g
el
(S
ca
rf
ad
e
),
si
li
co
n
e
g
el
sh
ee
t
(E
p
i-
D
er
m
T
M
)
an
d
o
n
io
n
ex
tr
ac
t
(C
o
n
tr
at
u
b
ex

)
(t
w
ic
e
d
ai
ly
)
o
n
p
o
st
-
b
u
rn
sc
ar
s.
S
y
m
p
to
m
s
as
se
ss
ed
v
ia
V
an
co
u
v
er
S
ca
r
S
ca
le
.
F
o
ll
o
w
-
u
p
fo
r
6
m
o
n
th
s
N
eg
at
iv
e/
n
eu
tr
al
—
si
li
co
n
e
p
ro
d
u
ct
s
re
sp
o
n
d
ed
b
et
te
r
th
an
C
o
n
tr
at
u
b
ex

4
C
h
u
n
g
et
al
.
[3
4
]
n
=
2
4
,
U
S
A
R
an
d
o
m
is
ed
d
o
u
b
le
-b
li
n
d
sp
li
t
sc
ar
st
u
d
y
C
o
m
p
ar
is
o
n
o
f
to
p
ic
al
p
et
ro
le
u
m
o
in
tm
en
t
w
it
h
o
n
io
n
ex
tr
ac
t
cr
ea
m
(M
ed
er
m
a
)
o
n
fr
es
h
su
rg
ic
al
w
o
u
n
d
s,
th
re
e
ti
m
es
d
ai
ly
fo
r
8
w
ee
k
s.
V
is
u
al
an
al
o
g
u
e
sc
al
e
u
se
d
to
as
se
ss
ap
p
ea
ra
n
ce
o
f
p
o
st
-
su
rg
ic
al
w
o
u
n
d
s
b
y
cl
in
ic
ia
n
s
an
d
p
at
ie
n
ts
.
1
2
w
ee
k
s
fo
ll
o
w
-u
p
,
te
le
p
h
o
n
e
in
te
rv
ie
w
af
te
r
1
1
m
o
n
th
s
N
eg
at
iv
e/
n
eu
tr
al
—
n
o
d
if
fe
re
n
ce
o
n
o
n
io
n
ex
tr
ac
t
tr
ea
tm
en
t
co
m
p
ar
ed
w
it
h
p
et
ro
le
u
m
o
in
tm
en
t
3
B
eu
th
et
al
.
[1
4
]
n
=
7
7
1
,
G
er
m
an
y
R
et
ro
sp
ec
ti
v
e
m
u
lt
i-
ce
n
tr
e
co
h
o
rt
st
u
d
y
O
n
io
n
ex
tr
ac
t
(C
o
n
tr
at
u
b
ex

)
o
n
p
o
st
-b
u
rn
sc
ar
s
an
d
h
y
p
er
tr
o
p
h
ic
/
k
el
o
id
sc
ar
s.
S
y
m
p
to
m
s
as
se
ss
ed
v
ia
V
an
co
u
v
er
S
ca
r
S
ca
le
.
F
o
ll
o
w
-
u
p
v
ar
ie
d
P
o
si
ti
v
e—
im
p
ro
v
ed
re
sp
o
n
se
co
m
p
ar
ed
w
it
h
co
rt
ic
o
st
er
o
id
tr
ea
tm
en
t,
w
it
h
le
ss
A
D
R
s
2
W
il
li
ta
l
an
d
S
im
o
n
[1
1
6
]
n
=
1
2
6
8
,
G
er
m
an
y
O
b
se
rv
at
io
n
al
,
n
o
n
-i
n
te
rv
en
ti
o
n
st
u
d
y
O
n
io
n
ex
tr
ac
t
(C
o
n
tr
at
u
b
ex

)
o
n
a
ra
n
g
e
o
f
sc
ar
s.
S
y
m
p
to
m
s
an
d
ap
p
ea
ra
n
ce
as
se
ss
ed
b
y
cl
in
ic
ia
n
an
d
p
at
ie
n
t
(s
ca
r
sc
al
e
u
ti
li
se
d
n
o
t
d
efi
n
ed
).
F
o
ll
o
w
-u
p
4
–
5
m
o
n
th
s
P
o
si
ti
v
e—
w
el
l
to
le
ra
te
d
,
an
d
im
p
ro
v
em
en
t
in
sc
ar
co
n
d
it
io
n
s
o
v
er
fo
ll
o
w
-u
p
p
er
io
d
2
M
u
an
g
m
an
et
al
.
[7
9
]
n
=
6
3
,
T
h
ai
la
n
d
R
et
ro
sp
ec
ti
v
e
ca
se
st
u
d
y
T
o
p
ic
al
ap
p
li
ca
ti
o
n
o
f
o
n
io
n
ex
tr
ac
t
(C
y
b
el
e
sc
ag
el
),
tw
ic
e
d
ai
ly
,
o
n
p
ar
ti
al
th
ic
k
n
es
s
b
u
rn
s.
S
y
m
p
to
m
s
as
se
ss
ed
v
ia
V
an
co
u
v
er
S
ca
r
S
ca
le
.
2
4
w
ee
k
s
fo
ll
o
w
-u
p
P
o
si
ti
v
e—
im
p
ro
v
es
p
li
ab
il
it
y
,
p
ig
m
en
ta
ti
o
n
,
it
ch
an
d
p
ai
n
o
v
er
th
e
st
u
d
y
p
er
io
d
3
C
am
p
an
at
i
et
al
.
[2
4
]
n
=
3
5
,
It
al
y
O
p
en
-l
ab
el
,
co
n
tr
o
ll
ed
,
n
o
n
-
ra
n
d
o
m
is
ed
cl
in
ic
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LOE4. The majority of studies looked at applying im-
iquimod after keloid shave excision, one followed excision
of melanocytic nevi [10] and one following breast surgery.
The follow-up period ranged from 8 weeks [10] to
12 months, the remainder of studies (n = 8) had follow-up
between 16 and 24 weeks or 6 months.
Seven studies led to a positive response, whereas three
studies were negative. One case–control study, utilising
imiquimod following breast augmentation indicated an
improved scar appearance compared with control treat-
ments [93]. A number of different case studies ([9] n = 12,
[76] n = 6, [105] n = 4) demonstrated a positive response
when used following ear keloid excision, preventing re-
currence [12, 76], and improving pruritus, pain and cos-
metic appearance over time [105]. The randomised case–
control study by Berman et al. [11] following keloid shave
excision, demonstrated an improvement, but there were not
enough patients (n = 20) to demonstrate a statistical sig-
nificance. The case study by Patel and Skinner [89]
demonstrated only one recurrence following ear keloid
excision in 60 patients. The case study by Chuansuwanich
and Gunjittisomram [33] (n = 45) concluded that im-
iquimod was more effective at preventing recurrence of
keloids excised from the earlobe than from other areas,
which may be linked to skin tension.
However, the prospective randomised controlled trial by
Berman et al. [10] of imiquimod following surgical exci-
sion of melanocytic nevi (n = 20) found no clinical or
cosmetic short-term benefit. The case study by Malhorta
et al. [73] (n = 2) indicated that discontinuation of im-
iquimod following presternal keloid excision led to recur-
rence within 4 weeks, although with the limited sample
size, it is difficult to draw firm conclusions. The case study
by Cacao et al. [23] (n = 9) concluded that imiquimod
failed to prevent recurrence after 20 weeks following sur-
gical excision of trunk keloids, although this could be re-
lated to anatomical location as many of the studies that
indicated a positive response were following keloid exci-
sion from the earlobe.
Mitomycin C
Mitomycin C is an anti-tumour antibiotic, which inhibits
DNA synthesis and cell proliferation, and is used to prevent
recurrence following keloid scar excision. Mitomycin C
inhibits keloid fibroblast proliferation in a cell culture
model [103], and was shown to improve response and re-
duce scarring following aerodigestive surgery [94]. While
this can be administered intralesionally, a number of pre-
liminary topical trials have been performed, applying
mitomycin C for 2–4 min directly following keloid exci-
sion. Seven different articles were identified for inclusion,
treating 84 patients in total [6, 30, 53, 96, 98, 106, 110]. All
of these were small case studies for treating keloids fol-
lowing surgical or shave excision, classified with an LOE
of 4. The shortest follow-up period was 2 months, the re-
mainder were all 6 months or more. Five studies led to a
positive response, whereas two studies drew neutral or
negative conclusions.
A retrospective case study, utilising mitomycin C fol-
lowing excision of head and neck keloids (n = 10) indi-
cated that recurrence was prevented in all but one patient
[106]. Several case studies following earlobe keloid shave
excision (Bailey n = 10, Chi n = 12 and Gupta n = 20)
concluded that patients and clinicians were satisfied with
the outcome, with scar improvement in almost all cases [6,
30, 53]. A further case series conducted by Seo and Sung
[98] (n = 9) concluded that topical mitomycin C treatment
led to a more favourable response, while wounds treated
with intralesional mitomycin C responded worse. However,
the case study by Sanders et al. [96] (n = 15) showed no
difference in keloid recurrence treated with or without
mitomycin C in combination with intralesional TAC. In the
case study by Talmi et al. [110] (n = 8), despite patients
appearing satisfied, mitomycin C failed to prevent
recurrence.
Plant extracts
A number of plant extracts, with a basis in traditional
medicine, marketed as ‘‘natural’’ alternatives, have been
used in a range of wound healing and cosmeceutical for-
mulations. Many are used in combination with other
treatment regimes, either formulated in creams or added to
dressings, to try and improve the conditions for wound
healing.
Onion extract
Onion extract contains a range of phenolic anti-oxidant and
anti-inflammatory compounds and were originally used for
treating full and partial thickness burns; however, more
recently these have been trialled for the treatment of hy-
pertrophic and keloid scarring, and healing wounds. Onion
extract and quercetin have been shown to reduced fibrob-
last proliferation in a cell culture mode, inducing matrix
metalloproteinase-1 expression, suggesting a role in ECM
remodelling [31]. For topical treatments for skin scarring
containing onion extract, 16 different articles were con-
sidered for inclusion, treating 2,703 patients [14, 24, 27,
32, 34, 42, 43, 56, 59, 63, 65, 69, 79, 87, 91, 116]. Of these,
however, two papers [14, 116], both ranked as LOE
category 2 were large retrospective analysis, with 771 and
1269 patients, respectively, and a third was a retrospective
case study [79], ranked as LOE 3 with 63 patients. Of the
remaining 13 articles (n = 600), two were randomised
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controlled trials [43, 63] ranked as LOE category 1, two
were randomised trials ranked as category 2 [42, 59] and
the remainder were smaller, randomised case–control
studies of varying sizes, ranked as LOE category 3 and 4.
Follow-up period ranged 2–6 months, with most (n = 8)
being 10–12 weeks.
The most commonly utilised onion extract products are
Mederma [34, 42, 43] and Contractubex [14, 56, 59, 65,
69, 87, 116], (both Merz Pharmaceuticals, LLC, Greens-
boro, North Carolina) Mederma is the US formulation
containing 10 % aqueous onion extract and 1 % allantoin,
whereas in addition, Contractubex (the European formu-
lation) contains 50 U heparin per gramme. The remaining
studies utilised Cybele Scagel [32, 63, 79] (Bangkok
Botanica, Bangkok, Thailand), Erase´ gel [27], (ABCA
Pharma Lab Co., Ltd., Nonthaburi, Thailand) and Kaloidon
gel [24] (Laboratori Farmacologici Milanesi, Milan, Italy).
Eleven of the studies identified reported positive expe-
riences with onion extract. Both of the large retrospective
studies concluded that Contractubex was well tolerated,
leading to an improved scar condition as assessed using a
range of scar scales and patient opinion over time [14,
116]. The randomised controlled trial by Ho et al. [56]
(n = 120) using Contractubex following laser-assisted
tattoo removal observed reducing scarring compared with
untreated control. Two randomised studies by Draelos in
2008 (n = 60) and 2012 (n = 44), following shave exci-
sion of seborrheic keratoses, concluded that Mederma
improved the appearance, signs and symptoms of the
healed wounds compared with untreated controls [42, 43];
however, both these studies note that funding was provided
by the manufacturer Merz Pharmaceuticals. The split-scar
analysis by Chanprapaph utilising Erase´ gel following
caesarean (n = 20) indicated improvement in scar height
and symptoms in the treated half, but no difference in
redness, pliability or overall appearance [27]. The three
studies ultilising Cybele Scagel following excision of
presternal hypertrophic scars ([63], n = 60), skin grafts
([32], n = 15) and partial thickness burns ([79], n = 63)
all concluded that the treatment led to a better response,
with respect to scar appearance and symptoms, than un-
treated wounds. The open-label non-randomised trial by
Campanati et al. [24] (n = 35) which used Kaloidon gel on
established keloid and hypertrophic scars concluded that
erythema was reduced and overall appearance improved
compared with the untreated controls. The randomised
blinded comparative study by Perez (n = 30), comparing
onion extract gel with a hydrocortisone, silicone and vi-
tamin E lotion to treat keloids and hypertrophic scars,
concluded both were more effective than placebo; im-
proving appearance, lesion induration and pigmentation.
However, hydrocortisone was more effective at improving
erythema and pigmentation [91].
Two studies concluded that combination therapy led to
improved scar response than individual treatments. The
open, randomised comparative study by Koc et al. [69]
(n = 27) determined that the combination of Contrac-
tubex and intralesional TAC was more effective at re-
lieving pain and itching in hypertrophic scars and keloids
than TAC alone. The comparative study by Hosunter et al.
[59] (n = 60) using Contractubex and silicone gel
sheeting to treat keloid and hypertrophic scars concluded
that co-administration led to the best response.
Three studies gave neutral or negative conclusions. The
randomised case–control study by Karagoz (n = 45) in
hypertrophic burn scars concluded that silicone gel sheet-
ing was more effective than Contractubex at improving
appearance and condition [65]. The randomised double-
blind split scar study by Chung et al. [34] (n = 24) fol-
lowing surgery, with Mederma compared with petrolatum
emollient found no difference between the two treatments.
The randomised controlled trial by Ocampo-Candaini
(n = 61) following caesarean determined that while pa-
tients liked Contractubex, there was no difference in the
improvement in POSAS scale scores over time compared
with no treatment; however, follow-up was only 12 weeks
in this study which may not have been enough time to
observe a significant response.
Green tea
Green tea (Camellia sinensis) contains phenolic com-
pounds, known as catechins, with anti-oxidant and anti-
inflammatory properties. Popular in traditional medicine
and as a beverage, topical application is thought to provide
a range of benefits, including a chemoprotective effect
against UV radiation [48]. Studies have demonstrated the
positive effect of the green tea polyphenol (-)-epigallo-
catechin-3-gallate (EGCG) in a keloid fibroblast culture
model, explaining its potential benefit in vivo. One study
showed significant inhibition of mast cell-stimulated type I
collagen expression via blocking of the PI-3K/AkT sig-
nalling pathways [121], another demonstrated significant
suppression of collagen production and proliferation via
inhibition of the STAT3-signalling pathway [88]. In a
punch biopsy, ex vivo culture model, EGCG was shown to
significantly inhibit growth and induce keloid shrinkage
[109].
Studies performed in animal models [29, 71] demon-
strated that EGCG has a positive effect on wound healing;
nevertheless, clinical trials in human subjects in the domain
of wound healing and scarring remain to be established.
Two trials were identified for inclusion in this study [40,
119] with a total of 41 patients. Both were ranked as LOE
category 4. The randomised split-faced trial in acne suf-
ferers by Yoon [119] (n = 37) demonstrated that EGCG
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was well tolerated, and effective at reducing symptoms and
inhibiting P. Acnes over the 8-week study period. Another
split-face pilot study by Domingo in patients with erythema
and telangiectasia (n = 4) demonstrated that although
symptoms did not improve, HIF-1a and VEGF expression
were reduced compared to vehicular control [40].
Aloe vera
A. vera has been used in traditional medicine for centuries;
however, the literature available for its use in wound
healing and skin scarring in particular is lacking. Following
the literature search, four articles were identified for in-
clusion in this review, two of which were systematic re-
views. One of these, a recent Cochrane systematic review
[39] (A. vera for treating acute and chronic wounds,
identifying 7 studies, involving 347 patients) concluded
that clinical evidence for the utility of A. vera in treating
acute and chronic wounds was mixed, and that firm con-
clusions of its effectiveness in improving the rate of wound
healing or the quality of the scar produced was lacking due
to the absence of high-quality trials and the range of dif-
ferent treatment settings and assessment criteria utilised.
Another systematic review [72], focussed on the use of A.
vera for treating burns, identified 4 studies with 371 pa-
tients. Although this study had found that average healing
time and the re-epithelialisation rate appeared to be re-
duced, there was no assessment of improvement or other-
wise in scar quality. As also concluded by other systematic
reviews included in this review, it was difficult to compare
the various methodologies and papers to draw firm con-
clusions as to the effectiveness of A. vera in this context.
Of the two remaining studies involving 79 patients, one
was ranked as LOE category 2 [51] and one as category 3
(Khorasani 2009 [67]), with both reaching positive con-
clusions in terms of the rate of initial wound healing ob-
served. The first, a randomised placebo controlled trial
utilising A. vera cream following hemorrhoidectomy
(n = 49), concluded that pain was reduced and the rate of
wound healing increased initially compared with placebo
treatment after 2 weeks, but after 4 weeks, the maximum
follow-up period of this study, there was no significant
difference between the two groups. No assessment of final
scar quality was made, with 4 weeks being too short a time
period for any conclusions regarding mature scar tissue to
be of relevance [51]. The second, a case–control study of
A. vera compared with silver sulfadiazine cream for the
treatment of second-degree burns (n = 30), indicated that
the rate of re-epithelisation and healing was greater with A.
vera. However, no assessment of healed burn scar quality
with respect to silver sulfadiazine control was made, and
follow-up was only 24 days [67].
Vitamin E
Vitamins have been used in topical cosmeceuticals and
moisturisers for decades, as an aid to improving skin
condition, and their anti-oxidant properties are thought to
help prevent UV damage in photo-aged skin. The most
commonly cited is vitamin E (tocotrienol). One review
concluded that evidence for its efficacy in wound healing
was lacking [55]. A survey and review of the use of vitamin
E to aid skin scarring concluded that although it is often
recommended by clinicians, evidence in the literature for
its efficacy is lacking [36].
Two studies utilising vitamin E following surgery were
identified [66, 120], totalling 550 patients. Both were
ranked as LOE category 2. The large prospective ran-
domised single-blinded study by Zampieri (n = 428)
assessed vitamin E both pre- and post-surgery in children.
Utilising the Vancouver Scar Scale, they summarised that
treated wounds were of better appearance with less prob-
lematic scarring than the placebo group after 6 months
[120]; however, this paper was criticised in relation to their
definition of keloid scarring, which should not be as
prevalent in young children of Italian ethnicity [82]. The
double-blind trial by Khoo following surgery (n = 122)
observed no change in overall scar appearance compared
with the placebo after 16 weeks [66].
Others
Several other studies were identified which looked at the
effect of topical treatments on skin scarring as primary
outcome. A randomised double-blind placebo controlled
trial by van der Veer et al. [113] (ranked LOE level 2) of
the use of topical vitamin D (calcipotriol) twice daily for
3 months following bilateral reduction mammoplasty
(n = 30) concluded that it had no effect in reducing the
occurrence of hypertrophic scarring compared with control
over the 12-month follow-up period.
Another commercially available product is moist ex-
posure burn ointment (MEBO, Julphar Gulf Pharma-
ceutical Industries, Ras Al-Khaimah, UAE). While this is
most commonly used for burns, two prospective studies
utilised MEBO to improve scar quality [5] and wound
healing [4] were identified (n = 126). Both were ranked
as LOE level 4, each comprising a range of individual
case studies and small randomised blinded trials with
6 months follow-up periods. The first (n = 60) conclud-
ed that cosmetic appearance of scars treated was im-
proved when compared with topical antibiotic (fudicin)
and untreated controls. The second (n = 66), in split
thickness skin grafts or following facial surgery, also
observed improved wound healing and scar formation. A
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new formulation, MEBO SCAReducer, is now also
available from the same manufacturer.
Discussion
The studies identified for inclusion in this review were
assessed according to their design and data by the rankings
defined by the Oxford Levels of Evidence (Table 2) [60–
62]. In summary, 39 articles were identified (excluding
systematic reviews and retrospective studies), with 1703
patients. The majority of articles were categorised as Level
4 (n = 23), with a relatively small number, less than 25 %,
being classified as robust studies (LOE 1 or 2, n = 9). In
all cases, there was conflicting evidence as to whether the
topical intervention was of benefit.
Several large systematic Cochrane Reviews have been
published, in the use of silicone gel sheeting for the pre-
vention of hypertrophic and keloid scars ([86]; 15 trials,
involving 615 patients), A. vera for treating acute and
chronic wounds ([39]; 7 trials, 347 patients), topical
treatment for facial burns ([57]; 5 RCT, 119 patients) and
honey as a topical treatment for wounds ([64], 25 trials
with a total of 2987 participants). The main conclusion
drawn from these reviews was that while several options
are available for treatment of a range of different scar
types, many of which are used extensively, there were no
large-scale studies with prolonged follow-up periods to
draw firm conclusions regarding long-term efficacy [44], a
recommendation which is also made by this review.
Common problems encountered during the preparation of
this review included the limited quality and individual
flaws with much of the available literature, in particular
low patient numbers, poor randomisation and blinding, the
range of different scar assessment methodologies used and
outcome measures reported, and short follow-up periods.
Results from clinical trials should be looked at cautiously,
especially due to the number of positively associated
clinical trials identified and the levels of evidence pre-
sented, as these may be subject to selection bias where
negative results are not published and therefore are not
available to review [47, 58].
Despite the volume of research into treatments for skin
scarring, there is little evidence to support many over-the-
counter treatments and cosmeceuticals available [122]. A
recent review concluded many of the advertising claims
made by these products cannot be substantiated [78]. This
is a common finding for many cosmeceuticals, as there is
no requirement to undertake clinical research, making it
difficult to critically evaluate the available evidence in
comparison to other approaches listed in this review.
It is difficult to randomise a trial based on wound
healing, or to compare between studies performed in dif-
ferent patient subsets and hospitals. Many factors such as
anatomical location, patient demographics and medical
history, surgical operation performed or the age and type of
scar, the injury that caused it and the lack of controls, are
impossible to standardise between trials [22]. Anatomical
location is of particular relevance with revision surgery for
keloid scarring; as summarised in the literature above, the
greatest rate of success across all treatments was with
earlobe keloids, with recurrence of keloids excised from
the sternum being most problematic. The follow-up period
for such studies should ideally be 12 months or more, to
ensure that the observed effect is due to treatment and not
the natural process of wound maturation which improves
over time; the majority of trials identified for inclusion in
this paper had follow-up periods of 6 months or less. A
further factor in interpreting the literature is the variability
in scar scales utilised and the subjective nature of assess-
ment; while many of the studies assessed in this review
rated scar symptoms such as inflammation, erythema, size,
scar contour, dryness and pruritus, in many cases these did
not relate their findings to a published and recognised
specific scar scale. In the literature cited in this review (see
Table 2 for references), the Vancouver Scar Scale [108]
was one of the commonly cited assessments of scar
symptoms [14, 32, 63, 65, 79, 98, 120]. This variability
made it particularly challenging to directly compare and
contrast the various studies identified. The subjective na-
ture of scar assessment could be limited by having different
clinicians independently analyse the same scars in each
study. An alternative issue is that many formulations
contain multiple ingredients, and their efficacy in combi-
nation is difficult to elucidate in the limited trials per-
formed. There are examples in the literature where a
combination of different approaches have shown success
[25], indicating how difficult the management of keloids
and problematic scarring can be.
There is an unmet clinical need for effective treatments
for skin scarring, in particular to address inflammation,
pruritus, dryness and redness, commonly cited by patients
as the factors which affect them most. Furthermore, robust
and consistent, large scale, clinical trials are required to
determine the effectiveness of these treatments. A number
of articles have summarised different treatment options
available for wound healing and scarring; however, these
focus on diagnosis and management, and do not review the
role of topical therapies in detail [2, 28, 75, 80]. These
currently recommend topical silicone gel or dressings
along with intralesional steroids and pressure therapy for
problematic scarring, and potential surgical revision if
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required. Based on the current levels of evidence presented
in this review, it is difficult to recommend the topical
treatments identified as alternatives to current practice
based on the limited clinical trial data currently available,
although some success has been shown when these are
utilised as supplementary therapy to standard practice in
addressing specific symptoms of concern.
What is clear from this review is that a standardised
and systematic approach and strategy for evaluating
scars prior to deciding on the appropriate treatment
regime is required (Fig. 2). Symptoms and signs, as well
as physical and psychosocial complaints, need to be
considered early, through use of objective scar assess-
ment scales and possibly tools, to elucidate the most
significant factors. The PRISM scale [18] potentially has
additional benefit in this context, as it includes a
patient’s perspective. Treatment, if appropriate, needs to
address these specific issues individually (Table 3;
Fig. 3). It is important to regularly monitor and re-e-
valuate response to therapy, particularly to assess signs
and symptoms as they change in response to treatment
and scar maturation. Thus, as symptoms and signs of the
scars change over time, a clinician’s approach with tar-
geted therapy would need to be altered. A greater
utilisation of a range of subjective and objective non-
invasive tools throughout this process, such as stan-
dardised photography, laser Doppler imaging, 3D cam-
eras, and SIAscopy, would likely aid interpretation and
evaluation of the skin scars, both in a research and
clinical setting, and lead to a more targeted treatment
based on managing problematic scar-related signs and
symptoms.
Fig. 2 A proposed flowchart
indicating the different stages of
the scar management timeline,
as recommended by the
corresponding senior author. A
structured clinical assessment is
required, taking into
consideration patient medical
and family history, including
current signs and symptoms and
utilising a range of quantitative
and qualitative measurements in
order to enable a targeted
treatment, which may evolve
over time as signs and
symptoms change
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Table 3 The known target and
effect of available topical
treatments in the processes of
wound healing, skin scarring
and abnormal raised dermal
scarring such as keloid and
hypertrophic scarring
Topical treatment Effect
Silicone gel/sheeting [1, 26, 92, 97, 117] Hydration and moisturisation
Improved skin/scar condition
Imiquimod [10–12, 23, 33, 73, 76, 89, 93, 105] Immune response modifier
Reduced proliferative effect
Reduced ECM expression
Mitomycin C [6, 30, 53, 94, 96, 98, 103, 106, 110] Anti-tumour antibiotic
Inhibits DNA synthesis and proliferation
Reduced fibroblast proliferation
Reduced ECM expression
Onion extract [14, 24, 27, 31, 32, 34, 42, 43, 56, 59,
63, 65, 69, 79, 87, 91, 116]
Anti-oxidant/anti-proliferative effect
Induction of MMP1
ECM remodelling
Reduced fibroblast proliferation
Green tea [29, 40, 48, 71, 88, 109, 119, 121] Anti-oxidant/anti-inflammatory effect
Reduced mast cell numbers
Inhibition of PI-3K/ART and STAT-3 pathways
Reduced collagen synthesis
Aloe vera [39, 51, 67, 72] Soothing/anti-inflammatory effect
Hydration and moisturisation
Improved skin/scar condition
Vitamin E [36, 55, 66, 120] Hydration and moisturisation
Improved skin/scar condition
Mechanisms of action abstracted from in vivo and in vitro data in currently available literature
Fig. 3 A flowchart depicting the effect of silicone gel and sheeting
[1, 26, 92, 97, 117], vitamin E [36, 55, 66, 120], Aloe vera [39, 51, 67,
72], green tea [29, 40, 48, 71, 88, 109, 119, 121], onion extract [14,
24, 27, 31, 32, 34, 42, 43, 56, 59, 63, 65, 69, 79, 87, 91, 116],
mitomycin C [6, 30, 53, 94, 96, 98, 103, 106, 110] and imiquimod
[10–12, 23, 33, 73, 76, 89, 93, 105] at addressing symptoms
commonly cited during wound healing, skin scarring and problematic
abnormal raised dermal scarring such as keloid and hypertrophic
scarring. The symptoms best targeted by the treatment are indicated,
as well as the known mechanistic target and resulting effect in vivo
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